Skip to main content
. Author manuscript; available in PMC: 2011 Jan 30.
Published in final edited form as: Oncogene. 2009 Jun 22;28(35):3121–3131. doi: 10.1038/onc.2009.168

Figure 3.

Figure 3

(a) Growth of human glioma cell lines stably transfected with Prkg2 (U-2987-P6, U-87-P1 and U-1242-P1) or empty pcDNA vector (denoted U-2987MG, U-87MG and U-1242MG) when treated with 250 μM of cyclic guanosine monophosphate (cGMP) analog over 7 days. M, million cells; Statistical significance: **P<0.01 and *P<0.05 using Student’s unpaired t-test (error bars indicate standard deviation from triplicates). (b) Flow cytometry of U-2987-MG glioma cells stably transfected with Prkg2 (U-2987-P6) or pcDNA (denoted U-2987MG) and treated with 250 μM of cGMP analog for 72 h.